SureTrader
Home > Boards > US OTC > Biotechs >

Intellect Neurosciences, Inc. (ILNS)

ILNS RSS Feed
Add ILNS Price Alert      Hide Sticky   Hide Intro
Moderator: Jumpinjackas, montanus, AlaskaBushMan, dbing
Search This Board:
Last Post: 2/12/2016 3:30:59 PM - Followers: 186 - Board type: Free - Posts Today: 0
 




INTELLECT NEUROSCIENCES


Intellect Neurosciences Inc. (OTCBB: ILNS) is a biopharmaceutical company engaged in the discovery and development of a new breed of innovative "disease-modifying" therapeutic drugs that are designed to slow, arrest and ultimately prevent Alzheimer's disease and other serious neurodegenerative disorders. 

Intellect is focused on neurodegenerative conditions collectively known as proteinopathies such as Alzheimer's, Parkinson's and Huntington disease.  Proteinopathies are caused by amyloidogenic proteins, such as amyloid beta, tau, alpha synuclein and Huntingtin.  Intellect is the first company to develop antibody drug conjugates (ADCs) in which amyloid clearing antibodies are empowered by chemically linking them to molecules that offer neuroprotection, creating a single drug.  The use of ADCs is one way in which Intellect is developing more effective drugs with the recognition that monotherapy may not be effective enough in treating the complex nature of proteinopathies. 

A second approach being pioneered by Intellect, also based on this idea and specifically focused on Alzheimer's disease, is a bi-specific vaccine that targets both beta amyloid and a pathogenic form of tau protein.  In contrast to antibodies that only target beta amyloid and have not yet proven their ability to treat mild to moderate Alzheimer's disease, the dual target vaccine being developed by Intellect has the potential to be used both prophylactically in presymptomatic patients and therapeutically in patients that are symptomatic.

Intellect Neurosciences has its origins in some of the earliest pioneering work that stimulated the development of the potential disease-modifying monoclonal antibodies that several global pharmaceutical companies have been testing as treatments for Alzheimer's disease. The intellectual property resulting from the discovery of how such antibodies could be used as treatments predates competitive strategies such that the pharmaceutical companies developing those drugs, purchased licenses to the technology from Intellect. The company remains ahead of the curve with respect to next-generation therapies, as it has developed multiple distinctive platform technologies that are generating drug candidates for a wide variety of diseases. 

The company developed OX1, a multimodal antioxidant molecule, through preclinical and human safety trials before licensing the program to ViroPharma.  ViroPharma has said it plans to enter Phase 2 clinical trials in patients with Friedreich's Ataxia, an orphan indication, in 2013.  Intellect could receive in excess of $100 million in milestone payments from ViroPharma and, if approved, royalties from sales over many years.

Intellect's preclinical R&D pipeline is based on two proprietary platform technologies, CONJUMAB-A and RECALL-VAX and includes the following drug candidates: 

CONJUMAB-A: Empowered Antibodies for the Treatment of Proteinopathies

N01-OX2 is a first-in-class ADC.  It is a humanized monoclonal antibody specific for beta amyloid protein that is empowered to deliver on-site neuroprotection by its conjugation to melatonin.  The goal of N01-OX2 is to reduce the oxidative stress that leads to cellular inflammation and damage.  N01-OX2 is being developed for the treatment of age-related macular degeneration (AMD), the leading cause of blindness in people over the age of 55. AMD therapies generate $4 billion annually, even though the few approved treatments don't cure the disease and offer only modest improvements in vision for most patients.  N01-OX2 also has potential applications for diabetic retinopathy, glaucoma, traumatic brain injury and Alzheimer's disease.

T01-OX2 is an ADC comprised of a monoclonal antibody selective for oligomeric toxic forms of tau protein and is empowered with neuroprotection by its conjugation to melatonin.  T01-OX2 is expected to reduce tau pathology and has potential for the treatment of Alzheimer's disease, Frontotemporal dementia and also has potential applications to treat ophthalmology indications.

RECALL VAX:  A chimeric peptide vaccine comprised of a human B cell epitope linked to a bacterial T cell epitope to produce highly specific vaccines against one or more amyloidogenic proteins.

RV03 is a first-in-class bi-specific vaccine targeting both beta amyloid and delta tau.  Delta tau is a shorter form of the tau protein.  It is especially toxic to nerve cells and precedes the formation of neurofibrillary tangles.  RV03 has potential for the treatment of Alzheimer's disease and Frontotemporal dementia. 

http://www.intellectns.com/
 
 PLATFORM TECHNOLOGIES

Intellect's preclinical R&D pipeline is based on four proprietary platform technologies: ANTISENILINÒ, CONJUMAB™, OLIGOTOPE™ and RECALL-VAX™


ANTISENILIN®: Free-end Specific Amyloid Beta Antibodies for Treatment of AD
 
IN-N01 is a humanized a high-affinity, stabilized, IgG4 therapeutic antibody that binds the amino terminus of amyloid beta without binding to the amyloid precursor protein (APP).
 
Antibodies exist in several isoforms; IgG1 antibodies have the strongest potential to induce inflammation while IgG4 has the lowest potential. IN-N01 is designed to promote the clearance of monomeric, oligomeric and plaque forms of amyloid beta, which accumulate in the brains of Alzheimer's patients or following traumatic brain injury and in the retina of the eye in patients with age-related macular degeneration, diabetic neuropathy and glaucoma.
 
CONJUMAB™: Empowered Antibodies for the Treatment of Proteinopathies
 
CONJUMAB-A is a first-in-class antibody drug conjugate for treatment of proteinopathies. IN-N01 has been empowered to deliver on-site neuroprotection by its conjugation to melatonin. Melatonin is a potent free radical scavenger and is an inhibitor of beta amyloid aggregation and previously shown to counteract the neurotoxicity associated with amyloid beta. Compounds based upon CONJUMAB-A are designed to reduce the oxidative stress and promote clearance of beta amyloid that is central to cellular inflammation and damage.
 
CONJUMAB-A is being developed for the treatment of age-related macular degeneration (AMD), the leading cause of blindness in people over the age of 55. CONJUMAB-A also has potential applications for diabetic retinopathy, glaucoma, traumatic brain injury, and Alzheimer's disease.
 
OLIGOTOPE™: Protein oligomer selective antibodies and methods of making them using chemically cross-linked stabilized aggregates as immunogens


TOC-1, our first compound utilizing the OLIOGOTOPE platform, is a murine monoclonal antibody selective for neurotoxic tau oligomers or aggregates considered to be the earliest pathogenic form of tau. Intellect plans to test TOC-01 as potential therapeutic for Alzheimer's disease and other tauopathies such as Frontotemporal dementia.
http://www.faqs.org/sec-filings/121015/Intellect-Neurosciences-Inc_10-K/#b
 
TauC3 specifically targets the neoepitope that is formed following cleavage of intact tau protein by proteolytic enzymes known as "executioner" caspases. This pathological process is stimulated by an accumulation of amyloid beta in the brain of Alzheimer's patients. It is believed that the smaller cleaved tau, referred to as delta tau, is especially toxic and prone to form tangles inside nerve cells and occurs early in the pathogenesis of the disease so antibody-mediated removal of delta tau would be expected to prevent the irreversible damage to nerve cells.
http://globenewswire.com/news-release/2013/02/07/521841/10020964/en/Intellect-Neurosciences-Initiates-in-vivo-Proof-of-Concept-Studies-in-a-Preclinical-Alzheimer-s-Model-for-Its-TauC3-Monoclonal-Antibody.html
 
 
RECALL VAX™: Chimeric peptide vaccine platform incorporating bacterial and human epitopes to target neoepitopes in pathological proteins
 
RV03, our first compound generated on the RECALL-VAX platform, is a first-in-class bi-specific vaccine targeting both beta amyloid and delta tau. Delta tau is a shorter form of the tau protein. It is especially toxic to nerve cells and precedes the formation of neurofibrillary tangles. RV03 has potential for the treatment of Alzheimer's disease and Frontotemporal dementias.
http://www.faqs.org/sec-filings/121015/Intellect-Neurosciences-Inc_10-K/#b

 


 

INTERNAL PIPELINE


Intellect Neurosciences has two preclinical programs it is developing internally.

One program under the RECALL-VAX platform has yielded two AD vaccine drug candidates, RV01 and RV02. RECALL-VAX™ has the potential to delay or prevent the development of Alzheimer's in those who are at risk by stimulating patients' immune systems to produce antibodies that clear amyloid betas and prevent further accumulation and deposition. Many view a vaccine of this nature, which is analogous to a flu shot, as the ultimate quest in Alzheimer's research.

Additionally,  CONJUMAB-A is Intellect's newly introduced platform technology for a novel class of therapeutics for treatment of Alzheimer's disease and other proteinopathies based on antibody-drug conjugates (ADCs).  The new ADC- based technology has the potential to improve on current methods of passive immunotherapy by increasing clearance of amyloid proteins while delivering potent cytoprotective molecules to sites of damage in the brain and other organs.  CONJUMAB-A is designed to reduce inflammation caused by amyloidosis while avoiding vasogenic edema, a side effect of plaque dissolution that occurs in some patients.   The company's lead CONJUMAB-A candidate is IN-N01-OX2, a non-activating, stabilized IgG4 humanized antibody specific for beta amyloid protein conjugated to melatonin, which is a naturally occurring molecule with potent anti-oxidant and anti-fibrillogenic properties. 

The Company has applied for a patent for its CONJUMAB-A technology. Intellect has the exclusively license to certain patents granted by the USPTO to NYU School of Medicine and the University of South Alabama Research Foundation specifically covering the use of melatonin for the treatment of Alzheimer's disease and other types of amyloidosis. The CONJUMAB-A platform is applicable to a broad range of diseases including, Alzheimer's, Parkinson's, Huntington's, Age-Related Macular Degeneration, Glaucoma, Cerebral Angiopathy, Frontotemporal Dementia, Progressive Supranuclear Palsy, Pick's disease, Cortical Basal Degeneration and Peripheral Amyloidosis.



http://www.intellectns.com/internal-pipeline

 
 

 
             

New Peer Reviewed Article Describes Role of TauC3 in AD Transgenic Mice

Marketwired

TauC3 Mice Showed Drastic Learning and Spatial Memory Deficits and Reduced Synaptic Density at a Young Age (2-3 months); First Published Study Describing Role of TauC3 in Vivo; Study Independently Conducted by Scientists at School of Biological Sciences, Seoul National University, Seoul, Republic of Korea

January 07, 2016: 08:36 AM ET

Intellect Neurosciences, Inc. (OTCQB: ILNS) ("Company" or "Intellect"), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of rare neurodegenerative conditions, today announced the publication of a scientific study of the role of TauC3 in transgenic mice in the prominent, peer-reviewed journal, Neurobiology of Disease [2015, 87:19-28]. The paper, titled "Caspase-cleaved tau exhibits rapid memory impairment associated with tau oligomers in a transgenic mouse model," describes the findings of a recent preclinical study of caspase-cleaved tau in a transgenic mouse model. The study marks the first published study indicating that the expression of caspase-cleaved tau (TauC3) in mice induces early memory deficit and reduced synaptic density. In addition, the study demonstrated that hyperphosphorylated tau oligomers and aggregates appear in TauC3 mice showing memory deficit and that aggregation blocker or rapamycin rescues memory impairment and reduces tau oligomers in TauC3 mice. The TauC3 mouse in the study is an Alzheimer's disease (AD) model used elucidate tau oligomer-associated pathogenesis and to evaluate therapeutic drug options. The paper was co-authored by scientists at the Global Research Laboratory, School of Biological Sciences, Seoul National University, Seoul, and the Department of Neurology and Neuroscience & Cell Biology, University of Texas, Galveston, Texas.

As described in the Abstract of the article, in neurodegenerative diseases like AD, tau forms neurofibrillary tangles, composed of tau protein. In the AD brain, activated caspases cleave tau at the 421th Asp, generating a caspase-cleaved form of tau, TauC3. Although TauC3 is known to assemble rapidly into filaments in vitro, the role of TauC3 in vivo remains unclear. In the study, scientists generated a transgenic mouse expressing human TauC3 using a neuron-specific promoter. The researchers found that human TauC3 was expressed in the hippocampus and cortex. Interestingly, the TauC3 mice showed drastic learning and spatial memory deficits and reduced synaptic density at a young age (2-3months). Notably, tau oligomers as well as tau aggregates were found in TauC3 mice showing memory deficits. These results suggest that TauC3 facilitates early memory impairment in transgenic mice accompanied with tau oligomer formation, providing insight into the role of TauC3 in the AD pathogenesis associated with tau oligomers and a useful AD model to test drug candidates.

Dr. Troy Rohn, Professor, Department of Biological Sciences, Boise State University, Boise, Idaho, Intellect's lead scientific advisor, commented, "This study is exciting because it provides proof-of-concept data regarding the role of TauC3 in various tauopathies. It is well known that the generation of the TauC3 fragment by caspases occurs in numerous neurodegenerative diseases and may facilitate the pathology associated with these disorders. However, to date, whether the TauC3 fragment itself can lead to behavioral deficits has been lacking. This in vivo study confirms that hypothesis and strongly supports targeting the TauC3 fragment as a therapeutic strategy in various diseases in which the fragment is produced."

In 2012, Intellect licensed a unique TauC3 antibody from Northwestern University, acquiring exclusive global rights to develop and commercialize the antibody. In January 2014, the Company announced top line data showing initial proof of concept in a preclinical Alzheimer's model, indicating the antibody's potential to be disease modifying. The study was conducted in collaboration with Dr. Frank LaFerla, University of California, Irvine, Chancellor's Professor and Chair, Neurobiology and Behavior School of Biological Sciences, Director, Institute for Memory Impairments and Neurological Disorders. The data showed that the TauC3 monoclonal antibody effectively engaged the target and reduced certain phosphorylated pathological forms of tau, indicating that the treatment with the peripherally administered antibody had an effect in the brain and potentially is disease modifying. In 2015, Intellect sponsored a research collaboration with Professor Bradley T. Hyman MD, PhD, Director, Massachusetts Alzheimer's Disease Research Center & Co-Director, Massachusetts General Hospital Memory Disorders Unit and John B. Penney Jr. Professor of Neurology, Harvard Medical School. The research project was designed to examine the detailed molecular mechanism affecting propagation of tau pathology and was aimed at developing a novel treatment for Alzheimer's disease and other tauopathies. The research yielded important data regarding target engagement, which the Company plans to use to strengthen its proprietary position in the TauC3 antibody. Intellect is planning to test its TauC3 monoclonal antibody in several orphan disease preclinical models in early 2016.

http://money.cnn.com/news/newsfeeds/articles/marketwire/11G077919-001.htm


 

Jan. 16, 2014, 3:20 a.m. EST

Intellect Neurosciences, Inc. Announces Positive Top Line Data Showing Proof of Concept in a Preclinical Alzheimer's Model for Its TauC3 Monoclonal Antibody Indicating its Potential to be Disease Modifying

Study indicates potential for TauC3 to be disease-modifying.

 

 

 

ENGLEWOOD CLIFFS, N.J., Jan 16, 2014 (GLOBE NEWSWIRE via COMTEX) -- via PRWEB - Intellect Neurosciences, Inc. ILNS +1.37% , a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic and diagnostic agents for the treatment of Alzheimer's and other neurological diseases, today announced it obtained proof of concept in a preclinical Alzheimer's model for its TauC3 monoclonal antibody indicating its potential to be disease modifying. The study was conducted in collaboration with University of California, Irvine's Dr. Frank LaFerla, Chancellor's Professor and Chair, Neurobiology and Behavior School of Biological Sciences, Director, Institute for Memory Impairments and Neurological Disorders as well as Dr. Kim Green and his team. The data showed that the TauC3 antibody effectively engaged the target and reduced certain phosphorylated pathological forms of Tau indicating that the treatment with the peripherally administered antibody had an effect in the brain and is able to be disease modifying. The investigators aim to publish the full data in a peer-reviewed scientific journal.

TauC3 specifically targets a fragment of Tau protein that is believed to result from beta-amyloid ("Aβ") induced cleavage of full length Tau by apoptotic caspase enzymes, early in the disease process leading to neuronal loss. The truncated tau ("delta tau", aka "TauC3" fragment) displays increased rates and extents of polymerization in vitro compared with wild-type full-length tau, suggesting a role for tau truncation in neurofibrillary tangle formation. Recently Professor Bradley Hyman's laboratory at Harvard Medical School also showed a critical role of this fragment in oligomeric Aβ-induced synaptic loss near Aβ plaques in the AD brain providing a mechanistic link between oligomeric Aβ and tau in AD (Polydoro et al., AAIC 2013, P2-048).

"We are gratified by this compelling proof of concept data independently generated by our collaborators at the University of California, Irvine." said Mr. Elliot Maza, a director of Intellect Neurosciences. "These important new data and growing strength of our revitalized patent portfolio, including the recent patent Allowance from the USPTO in relation to the TOC-1 monoclonal antibody targeting oligomeric tau, underscore our leadership in this area and should attract significant renewed interest from the pharmaceutical industry".

Intellect Neurosciences holds worldwide development and commercialization rights to TauC3 under an exclusive license agreement with Northwestern University. Also, Intellect owns pending patent applications relating to antibodies targeting fragments of Tau in the brain for treatment of Alzheimer's and other tauopathies (e.g. Chain, 2011: Treatment of Tauopathies, WO 2012/106363 published November 15, 2012).

About Intellect Neurosciences

Intellect Neurosciences, Inc. develops innovative approaches aimed at arresting or preventing Alzheimer's disease and other neurodegenerative diseases, with a specific focus on proteinopathies. Intellect's pipeline includes, antibodies and neuroprotective antibody drug conjugates. For more information, please visit http://www.intellectns.com .

Safe Harbor Statements Regarding Forward Looking Statements

The statements in this release and oral statements made by representatives of Intellect Neurosciences relating to matters that are not historical facts (including, without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those discussed in Intellect's Annual Report on Form 10-K (file no. 333-128226) filed on October 15, 2013 and Quarterly Report on Form 10-Q (file no. 333-128226), filed on November 19, 2013.

Contact:

http://www.ir (at)intellectns(dot)com

This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visithttp://www.prweb.com/releases/2014/1/prweb11489644.htm

 
                  

Intellect Neurosciences Obtains Patent Allowance From the United States Patent and Trademark Office in Relation to Its TOC-1 Monoclonal Antibody Selective for Pre-Fibrillar Tau Aggregates

Published: November 14, 2013

NEW YORK, Nov. 14, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc.(OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic and diagnostic agents for the treatment of Alzheimer's and other neurological diseases, today announced it obtained a Notice of Allowance from the United States Patent and Trademark Office (USPTO). The patent allowance is in relation to TOC-1, a monoclonal antibody that selectively binds neurotoxic pre-fibrillar tau aggregates which are important pathological components in Alzheimer's disease (AD) and other neurodegenerative tauopathies. Intellect previously obtained development and commercialization rights to TOC-1 under an exclusive license agreement withNorthwestern University.  

New findings regarding the antibody were recently published in the Journal of Alzheimer's Disease in a paper titled, "TOC1: Characterization of a Selective Oligomeric Tau Antibody" written by Lester Binder, Ph.D., the Abbott Laboratories, Duane and Susan Burnham Research Professor of Genetic and Molecular Medicine, at Northwestern University. These data underscore its potential as a powerful biochemical tool that can be used to better investigate the involvement of tau in neurodegenerative diseases.  

"The new patent allowance from the USPTO awarded to Intellect Neurosciences is of particular significance in view of the considerable attention being given to the important role of pre-fibrillar aggregated forms of tau in the pathogenesis of AD and other tauopathies such as cortico-basal ganglia degeneration and progressive supranuclear palsy," said Professor Moses V. Chao, Molecular Neurobiology Program Skirball Institute of Biomolecular Medicine NYU School of Medicine.  "TOC-1 reacts with brain pathology in each of these types of diseases and is undoubtedly an important biochemical tool that will be extremely helpful to academic and industry researchers". 

The Company is exploring ways to commercialize TOC-1, initially as an essential tool which is required for research, but also for further development clinically.

About Intellect Neurosciences

Intellect Neurosciences, Inc. develops innovative approaches aimed at arresting or preventing Alzheimer's disease and other neurodegenerative diseases, with a specific focus on proteinopathies. Intellect's pipeline includes therapeutic vaccines, antibodies and neuroprotective antibody drug conjugates. For more information, please visitwww.intellectns.com.

hp://markets.on.nytimes.com/research/stocks/news/press_release.asp?docTag=201311141415PRIMZONEFULLFEED10058120&feedID=600&press_symbol=7460483

 



MILESTONE PAYMENT

ANTISENILIN®

http://www.prnewswire.com/news-releases/intellect-neurosciences-receives-notice-of-allowance-from-united-states-patent-and-trademark-office-for-its-antisenilin-alzheimers-disease-immunotherapy-technology-platform-141561013.html
http://www.intellectns.com/platform-technologies/antisenilin


Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy

This study is ongoing, but not recruiting participants.
Sponsor:
Pfizer
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01821118
First received: March 4, 2013
Last updated: May 14, 2015
Last verified: May 2015

https://www.clinicaltrials.gov/ct2/show/NCT01821118?term=ponezumab&rank=8
 

 

Drug Profile

Indolepropionic acid - ViroPharma

Alternative Names: Indole-3-propionic acid; IPA - ViroPharma; OX-1; Oxigon; SHP622; VP-20629

Latest Information Update: 28 Aug 2015

At a glance

 

  • OriginatorNew York University; University of South Alabama
    DeveloperIntellect Neurosciences; Shire ViroPharma
    ClassAntidementias; Indoles; Neuroprotectants; Propionic acids; Small molecules
    Mechanism of ActionAmyloid inhibitors; Antioxidants; Chelating agents; Free radical scavengers; Protein aggregation inhibitors
  • Orphan Drug StatusNo
    On Fast trackNo
    New Molecular EntityYes

Highest Development Phases

  • Phase IFriedreich's ataxia
    No development reportedAlzheimer's disease

Most Recent Events

  • 01 Jul 2015Shire ViroPharma completes a phase I trial in Friedreich's ataxia in USA (NCT01898884)
    11 Mar 2014ViroPharma is now called Shire ViroPharma
    24 Jan 2014ViroPharma has been acquired by Shire
http://adisinsight.springer.com/drugs/800017707
 

 
STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL 
 
USAN PONEZUMAB 
PRONUNCIATION poe nez' oo mab 
THERAPEUTIC CLAIM Treatment of Alzheimer’s disease 
CHEMICAL NAMES 
1. Immunoglobulin G2, anti-(human ß-amyloid) (human-mouse monoclonal PF-04360365 
clone 9TL heavy chain), disulfide with human-mouse monoclonal PF-04360365 
clone 9TL light chain, dimer 
2. Immunoglobulin G2, anti-(human amyloid beta A4 protein (Alzheimer disease amyloid 
protein, ABPP, APPI, preA4, protease nexin-II)); humanized mouse monoclonal 
PF-04360365 clone 9TL des-442-lysine(CH3107-K)-[325-serine(CH299A>S),326- 
serine(CH2100P>S)]?2 heavy chain (130-219')-disulfide with humanized mouse 
monoclonal PF-04360365 clone 9TL ? light chain, dimer (218-218'':219-219'':222- 
222':225-225'')-tetrakisdisulfide 
MOLECULAR FORMULA C6552H10158N1730O2090S52 
MOLECULAR WEIGHT 148.3 kDa 
TRADEMARK None as yet 
MANUFACTURER Pfizer, Inc. 
CODE DESIGNATION PF-04360365, RN-1219 
CAS REGISTRY NUMBER 1178862-65-1 
 
 
 
 
 
 
 
  

 
ILNS Security Details
Share Structure
  Market Value1 $456,497 a/o Jan 26, 2016
  Authorized Shares 2,000,000,000 a/o Nov 04, 2015
  Outstanding Shares 5,567,037 a/o Nov 04, 2015
  -Restricted Not Available
  -Unrestricted Not Available
  Held at DTC Not Available
  Float 4,717,663 a/o Nov 04, 2015
  Par Value Not Available
 







 
Security Notes

Capital Change=shs decreased by 1 for 50 split Pay date=04/12/2011.
Capital Change=shs decreased by 1 for 250 split. Pay date=02/11/201
5.

http://www.otcmarkets.com/stock/ILNS/profile
 


                                                             

 


 


 

 


 


 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ILNS
Current Price
Volume:
Bid Ask Day's Range
Wiki
ILNS News: Statement of Ownership (sc 13g) 02/05/2016 12:43:08 PM
ILNS News: Current Report Filing (8-k) 12/08/2015 04:51:51 PM
ILNS News: Quarterly Report (10-q) 11/12/2015 06:01:19 PM
ILNS News: Current Report Filing (8-k) 10/26/2015 03:24:28 PM
ILNS News: Current Report Filing (8-k) 10/21/2015 01:33:57 PM
PostSubject
#19386  Sticky Note Reality Check. AlaskaBushMan 01/13/16 05:04:35 PM
#19537   Same. As of December 31, 2015, we had approximately Jumpinjackas 02/12/16 03:30:59 PM
#19536   10-Q is out for ILNS....at work and no john1045 02/12/16 03:07:28 PM
#19535   Ok you see when they publish the results. itwillgetbetter 02/12/16 12:30:47 PM
#19534   Your concrete proof is as factual as Elliot's Jumpinjackas 02/12/16 08:47:56 AM
#19533   Or it could simply be someone stuck with nsomniyak 02/11/16 11:33:47 PM
#19532   Again I don't really care. If they screwed itwillgetbetter 02/11/16 10:13:33 PM
#19531   That has to be mm trades/prods because the Jumpinjackas 02/11/16 02:58:37 PM
#19530   Seventeen shares traded today. Seems about right. Stately 02/11/16 02:29:42 PM
#19529   OK. I was just trying to say. We Jumpinjackas 02/11/16 12:28:57 PM
#19528   To be frank I don't give a chit itwillgetbetter 02/11/16 11:58:13 AM
#19527   It's a blinded study. It's great that dsmb Jumpinjackas 02/11/16 10:47:22 AM
#19526   Yeah been keeping up with it. Its pretty itwillgetbetter 02/11/16 09:47:35 AM
#19525   Shire earnings report released today. SHP-622 still listed Stately 02/11/16 09:14:55 AM
#19524   I'm laughing on that one myself. Hey less itwillgetbetter 02/11/16 08:46:25 AM
#19523   Ha ha.. What goes around comes around? Funny Jumpinjackas 02/11/16 08:11:00 AM
#19522   Chris Christie - Statement from Elliot Maza montanus 02/11/16 07:18:43 AM
#19521   Oh Hum, going to have to cut the buckiii2 02/10/16 12:12:13 PM
#19520   It would sure as hell make for a tyfoidhana 02/09/16 08:54:19 PM
#19518   I hear you Jumpin I'm no longer rational tyfoidhana 02/09/16 08:49:20 PM
#19517   LOL I'm in the same boat. I buy itwillgetbetter 02/09/16 07:47:07 PM
#19516   There is one fact. That is a fact, Drs136 02/09/16 06:53:35 PM
#19515   It really is a moot issue if Elliot itwillgetbetter 02/09/16 03:22:47 PM
#19514   I'm not saying it has to be at Dubb10 02/09/16 02:49:29 PM
#19513   I don't buy into the theory the A/S itwillgetbetter 02/09/16 02:44:54 PM
#19512   They have an earnings call on Thursday at Dubb10 02/09/16 01:25:12 PM
#19511   I just wish they would release the data, results. Jumpinjackas 02/09/16 01:19:56 PM
#19510   Shire would have to gain the majority of Dubb10 02/09/16 01:00:38 PM
#19509   I hope you right cause you seem to itwillgetbetter 02/09/16 12:41:28 PM
#19508   https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001557-27/NL buckiii2 02/09/16 10:20:57 AM
#19507   Nice find. They have resource dedicated to it. Jumpinjackas 02/09/16 09:41:51 AM
#19506   https://www.linkedin.com/in/mark-lillie-28525623?trk=seokp-title_posts_secondary buckiii2 02/09/16 09:26:42 AM
#19505   I'm digging the feeling that an investment I Stately 02/09/16 09:15:15 AM
#19504   No, they've had discussions. That was evident in Jumpinjackas 02/09/16 08:53:31 AM
#19503   Are there any milestones associated with this? Jumpinjackas 02/09/16 08:38:49 AM
#19502   PONEZUMAB PHASE II STUDY HAS BEEN COMPLETED - montanus 02/09/16 07:50:56 AM
#19501   That would have to be a guess as Jumpinjackas 02/09/16 01:35:32 AM
#19500   Seems you know what and how and I'm itwillgetbetter 02/08/16 05:47:41 PM
#19499   You think we could be setting up to tyfoidhana 02/08/16 05:36:24 PM
#19498   Its a dam shame drug trials are not tyfoidhana 02/08/16 05:30:25 PM
#19497   I'm only speaking from being involved Randomized Controlled Jumpinjackas 02/08/16 04:33:21 PM
#19496   You are mistaken I know what was said itwillgetbetter 02/08/16 04:25:33 PM
#19495   Just to add, the ADE items are reported Jumpinjackas 02/08/16 03:39:39 PM
#19494   I still don't get that part, serious of Jumpinjackas 02/08/16 03:36:59 PM
#19493   All I needed was for a win but itwillgetbetter 02/08/16 03:27:59 PM
#19492   It's hard to read the delay. It's been Jumpinjackas 02/08/16 03:01:29 PM
#19491   I knew they could shock people if the Jumpinjackas 02/08/16 02:54:36 PM
#19490   Wealthy people don't get that way by viewing Stately 02/08/16 01:41:53 PM
#19489   Well that was pocket change to him. I itwillgetbetter 02/08/16 01:40:04 PM
#19488   I never understand that dozen share buys and sells. Jumpinjackas 02/08/16 11:38:40 AM
#19487   I got the same feeling with this recent filing john1045 02/08/16 11:15:25 AM
PostSubject